Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment

Frontiers in Immunology

Caterina Cancrini¹  Beatrice Rivalta¹  Andrea Finocchi¹  Paolo Rossi¹  Lucia Pacillo¹  Cristina Russo³  Carlo Federico Perno³  Luna Colagrossi³  Leonarda Gentile³  Carmela Giancotta⁴  Paola Zangari⁴  Emma Concetta Manno⁴  Veronica Santilli⁴  Donato Amodio⁴  Paolo Palma⁴  Nicola Cotugno⁴  Stefania Bernardi⁵ 

[1] Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy;Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy;Multimodal Medicine Research Area, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy;Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics (DPUO), Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy;Research Unit of Primary Immunodeficiencies, Immune and Infectious Diseases Division, Academic Department of Pediatrics (DPUO), Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy;

关键词: SARS-CoV-2;    COVID19;    IEI;    activated PI3K delta syndrome (APDS);    monoclonal antibody;    remdesivir;   

DOI  :  10.3389/fimmu.2022.891274

来源: DOAJ

【 摘 要 】

We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies’ good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.

【 授权许可】

Unknown